279 related articles for article (PubMed ID: 7918071)
1. Point mutations of the N-ras gene in the blood plasma DNA of patients with myelodysplastic syndrome or acute myelogenous leukaemia.
Vasioukhin V; Anker P; Maurice P; Lyautey J; Lederrey C; Stroun M
Br J Haematol; 1994 Apr; 86(4):774-9. PubMed ID: 7918071
[TBL] [Abstract][Full Text] [Related]
2. The prognostic significance of bone marrow levels of neurofibromatosis-1 protein and ras oncogene mutations in patients with acute myeloid leukemia and myelodysplastic syndrome.
Lu D; Nounou R; Beran M; Estey E; Manshouri T; Kantarjian H; Keating MJ; Albitar M
Cancer; 2003 Jan; 97(2):441-9. PubMed ID: 12518368
[TBL] [Abstract][Full Text] [Related]
3. Multiple point mutation of N-ras and K-ras oncogenes in myelodysplastic syndrome and acute myelogenous leukemia.
Nakagawa T; Saitoh S; Imoto S; Itoh M; Tsutsumi M; Hikiji K; Nakamura H; Matozaki S; Ogawa R; Nakao Y
Oncology; 1992; 49(2):114-22. PubMed ID: 1574246
[TBL] [Abstract][Full Text] [Related]
4. Prevalence of N-ras mutations in children with myelodysplastic syndromes and acute myeloid leukemia.
Lübbert M; Mirro J; Kitchingman G; McCormick F; Mertelsmann R; Herrmann F; Koeffler HP
Oncogene; 1992 Feb; 7(2):263-8. PubMed ID: 1549347
[TBL] [Abstract][Full Text] [Related]
5. N-ras mutations are associated with poor prognosis and increased risk of leukemia in myelodysplastic syndrome.
Paquette RL; Landaw EM; Pierre RV; Kahan J; Lübbert M; Lazcano O; Isaac G; McCormick F; Koeffler HP
Blood; 1993 Jul; 82(2):590-9. PubMed ID: 8329714
[TBL] [Abstract][Full Text] [Related]
6. Occurrence of point mutations in p53 gene is not increased in patients with acute myeloid leukaemia carrying an activating N-ras mutation.
Bühler-Leclerc M; Gratwohl A; Senn HP
Br J Haematol; 1993 Jul; 84(3):443-50. PubMed ID: 8217795
[TBL] [Abstract][Full Text] [Related]
7. Retrospective analysis of ras gene activation in myeloid leukemic cells.
Lübbert M; Jonas D; Miller CW; Herrmann F; Mertelsmann R; McCormick F; Koeffler HP
Oncogene; 1990 Apr; 5(4):583-7. PubMed ID: 2183160
[TBL] [Abstract][Full Text] [Related]
8. Clonality studies and N-ras and p53 mutation analysis of hematopoietic cells in Fanconi anemia.
Venkatraj VS; Gaidano G; Auerbach AD
Leukemia; 1994 Aug; 8(8):1354-8. PubMed ID: 8057673
[TBL] [Abstract][Full Text] [Related]
9. [Activation of ras oncogene in myelodysplastic syndrome and acute myelogenous leukemia].
Hirai H; Hirano N; Yazaki Y
Gan To Kagaku Ryoho; 1991 Jun; 18(7):1090-7. PubMed ID: 2053767
[TBL] [Abstract][Full Text] [Related]
10. Ras point mutations occur in acute myeloid leukemia with illegitimate T-cell receptor delta gene rearrangement.
Schmidt CA; Przybylski G; Vogel D; Ludwig WD; Oettle H; Neubauer A; Siegert W
Leukemia; 1994 Jan; 8(1):102-5. PubMed ID: 8289473
[TBL] [Abstract][Full Text] [Related]
11. Mutations of N-ras oncogene in myelodysplastic syndromes and leukemias detected by polymerase chain reaction.
Mano H; Ishikawa F; Hirai H; Takaku F
Jpn J Cancer Res; 1989 Feb; 80(2):102-6. PubMed ID: 2498243
[TBL] [Abstract][Full Text] [Related]
12. Mutations of the p53 gene in myelodysplastic syndrome and overt leukemia.
Mori N; Hidai H; Yokota J; Okada M; Motoji T; Oshimi K; Mizoguchi H
Leuk Res; 1995 Nov; 19(11):869-75. PubMed ID: 8551805
[TBL] [Abstract][Full Text] [Related]
13. Analysis of mutations of neurofibromatosis type 1 gene and N-ras gene in acute myelogenous leukemia.
Lee YY; Kim WS; Bang YJ; Jung CW; Park S; Yoon WJ; Cho KS; Kim IS; Jung TJ; Choi IY
Stem Cells; 1995 Sep; 13(5):556-63. PubMed ID: 8528106
[TBL] [Abstract][Full Text] [Related]
14. Monosomy 7 myelodysplastic syndrome and other second malignant neoplasms in children with neurofibromatosis type 1.
Maris JM; Wiersma SR; Mahgoub N; Thompson P; Geyer RJ; Hurwitz CG; Lange BJ; Shannon KM
Cancer; 1997 Apr; 79(7):1438-46. PubMed ID: 9083167
[TBL] [Abstract][Full Text] [Related]
15. No concomitant occurrence of the N-ras and p53 gene mutations in myelodysplastic syndromes.
Mitani K; Hangaishi A; Imamura N; Miyagawa K; Ogawa S; Kanda Y; Yazaki Y; Hirai H
Leukemia; 1997 Jun; 11(6):863-5. PubMed ID: 9177441
[TBL] [Abstract][Full Text] [Related]
16. Hyperactivation of the RAS signaling pathway in myelodysplastic syndrome with AML1/RUNX1 point mutations.
Niimi H; Harada H; Harada Y; Ding Y; Imagawa J; Inaba T; Kyo T; Kimura A
Leukemia; 2006 Apr; 20(4):635-44. PubMed ID: 16467864
[TBL] [Abstract][Full Text] [Related]
17. High Expression of Human Homologue of Murine Double Minute 4 and the Short Splicing Variant, HDM4-S, in Bone Marrow in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome.
Han X; Medeiros LJ; Zhang YH; You MJ; Andreeff M; Konopleva M; Bueso-Ramos CE
Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S30-8. PubMed ID: 27155969
[TBL] [Abstract][Full Text] [Related]
18. Persistence of an activating N-RAS oncogene mutation in clonogenic progenitor cells from an acute myeloid leukaemia patient in remission.
Zaheer HA; Bagnara M; Gibson FM; Robinson G; Rutherford TR; Gordon-Smith EC
Br J Haematol; 1994 Feb; 86(2):298-302. PubMed ID: 8199018
[TBL] [Abstract][Full Text] [Related]
19. [Molecular study on minute alterations of the p53 and the N-ras genes in hematologic malignancies].
Kurosawa M
Hokkaido Igaku Zasshi; 1994 May; 69(3):543-54. PubMed ID: 7927179
[TBL] [Abstract][Full Text] [Related]
20. Possible co-existence of RAS activation and monosomy 7 in the leukaemic transformation of myelodysplastic syndromes.
Stephenson J; Lizhen H; Mufti GJ
Leuk Res; 1995 Oct; 19(10):741-8. PubMed ID: 7500652
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
